Clinical research results and efficacy of adagrasib (Krazati) in the treatment of non-small cell lung cancer

Adagrasiib (Krazati) is an oral small molecule targeted drug specifically targeted at patients with KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). KRAS G12C is one of the more common driver gene mutations in NSCLC . Traditional chemotherapy and immunotherapy have limited efficacy in such patients. Adagrasib selectively inhibits the activity of mutated KRAS protein and blocks downstream signaling pathways, thereby inhibiting tumor cell proliferation and inducing apoptosis, providing a precise targeted treatment solution for patients with advanced stages or previous treatment failures.

Multiple clinical studies have shown that adagrasib shows significant efficacy in KRAS G12CpositiveNSCLC patients. In the first-line or previously chemotherapy-treated patient population, the objective response rate (ORR) is approximately 40% to 45%, and most patients achieve partial or complete response. In addition, the drug also shows positive effects in prolonging progression-free survival (PFS) and improving symptoms. Some patients can significantly relieve symptoms such as cough, dyspnea, and decreased physical strength after taking the drug for several months, improving the overall quality of life.

The efficacy of adagrasib in patients with brain metastases is also worthy of attention. Clinical data shows that the drug has a certain ability to penetrate the blood-brain barrier. Some patients with brain metastases have seen their brain lesions shrink in size or stabilize their condition after receiving treatment. This feature provides KRAS G12C-positive NSCLC patients with more comprehensive treatment options, especially when traditional therapies have limited control over brain metastases. Adagarasib exhibits unique clinical advantages.

Overall, adagrasib has clear clinical value in patients with KRAS G12C positive non-small cell lung cancer. Its targeted efficacy is stable and it can improve patients' exercise tolerance and quality of life. Although attention still needs to be paid to the resistance mechanism and long-term efficacy maintenance issues, current research results show that adagrasib provides a feasible targeted treatment option for patients with such special mutations and provides a new direction for clinical treatment strategies.

Reference link:https://www.drugs.com